Literature DB >> 20011211

The ethics of antenatal screening: lessons from Canute.

Timothy M Reynolds1.   

Abstract

Modern medicine has given us the power to identify many diseases before they occur and apply preventative measures so that morbidity and mortality may be avoided. When these screening measures are offered to someone who is capable of making an informed decision to proceed, they may be uncontroversial but may actually cause more harm than good. In antenatal screening, it is difficult to define who the patient is, because there are several possibilities: the pregnant woman, the foetus, or the family. Consequently, it can be difficult to identify whether the treatment offered is in the best interest of all concerned. Our growing knowledge about the human genome will in future give us more power to be able to identify undesirable traits, but there is no strict definition where the line of acceptability lies. The eugenic excesses of the mid-20(th) century are often cited as a reason why antenatal screening is bad. The story of King Canute informs us that defining a 'line in the sand' cannot prevent the rising tide of medical capability overwhelming any arbitrary level of acceptability. This paper discusses the history of eugenics from Sparta to the modern day and attempts to give some perspective on this crucial policy area. No one paper can provide the answer: it is necessary that society as a whole debates where it wishes to go...

Entities:  

Year:  2009        PMID: 20011211      PMCID: PMC2791772     

Source DB:  PubMed          Journal:  Clin Biochem Rev        ISSN: 0159-8090


  43 in total

1.  Human genetic improvement: a comparison of Russian and British public perceptions.

Authors:  L Gudkov; P Tichtchenko; B Yudin
Journal:  Bull Med Ethics       Date:  1998-01

2.  In the name of public health--Nazi racial hygiene.

Authors:  Susan Bachrach
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

3.  Mass screening: theory and ethics.

Authors:  D Mant; G Fowler
Journal:  BMJ       Date:  1990-04-07

Review 4.  ABC of antenatal care. Detection and management of congenital abnormalities--I.

Authors:  G Chamberlain
Journal:  BMJ       Date:  1991-04-20

5.  Screening for Down's syndrome using serum alpha fetoprotein: a retrospective study indicating caution.

Authors:  K Spencer; P Carpenter
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-29

6.  IFCC position paper: report of the IFCC taskforce on ethics: introduction and framework.

Authors:  Leslie Burnett; Matthew J McQueen; Jon Johannes Jonsson; Francesca Torricelli
Journal:  Clin Chem Lab Med       Date:  2007       Impact factor: 3.694

7.  Women's decision-making in prenatal screening.

Authors:  P Santalahti; E Hemminki; A M Latikka; M Ryynänen
Journal:  Soc Sci Med       Date:  1998-04       Impact factor: 4.634

8.  Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome.

Authors:  N J Wald; H S Cuckle; J W Densem; K Nanchahal; J A Canick; J E Haddow; G J Knight; G E Palomaki
Journal:  Br J Obstet Gynaecol       Date:  1988-04

9.  Maternal serum alpha-fetoprotein, age, and Down syndrome risk.

Authors:  G E Palomaki; J E Haddow
Journal:  Am J Obstet Gynecol       Date:  1987-02       Impact factor: 8.661

10.  Screening for fetal Down's syndrome in pregnancy by measuring maternal serum alpha-fetoprotein levels.

Authors:  M S DiMaio; A Baumgarten; R M Greenstein; H M Saal; M J Mahoney
Journal:  N Engl J Med       Date:  1987-08-06       Impact factor: 91.245

View more
  1 in total

1.  The triple test as a screening technique for Down syndrome: reliability and relevance.

Authors:  Tim Reynolds
Journal:  Int J Womens Health       Date:  2010-08-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.